Immunomodulatory drug in secondary immunodeficiency states

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to immunomodulatory drugs. Application Helepin D or Helepin as an immunomodulatory drug in secondary immunodeficiency states.

EFFECT: Helepin D or Helepin possess effective immunomodulatory action in immunodeficiency states.

1 dwg, 4 tbl, 3 ex

 

The invention relates to chemical-pharmaceutical industry, namely the use of herbal medicines as immune-modulating means. The closest analogue to the claimed invention is a tool that has broad pharmacological properties, in particular high antiviral activity against DNA genome of the virus, and patented in several foreign countries, it is a natural individual compound of ksenonovoi nature of the composition of the C19C18O11(mangiferin)obtained from two types of material Hedysarum (Hedyzarum alpium L., H.flavescens Rql. et Smalh. the legume family - Fabaceae) and leaves of mango (Mangifera indica L.) Mangifera family (Anacardiaceae) [Vechkanov S.A., Ludhiyana, Vigasin, USSR Author's certificate No. 1336301. Patents: England No. 2108383; U.S. No. 4436732, CL AC 37/02, 1989; France, No. 81198820; Germany No. 31411970; EN 23089612, 27.10.2007].

The disadvantages are:

1. The emergence alpizarina embryotoxic effect, resulting in the impossibility of its use in pregnancy and lactation for treatment of herpes infections.

2. Alpizarin as an immunomodulating tools in medical practice.

The objective of the invention is the expansion of the range of immunomodulating agents of plant is about the origin, as well as creating medicines that are not available with the prototype defects and exhibiting effective immunomodulatory effects with secondary immunodeficiency.

Research on search and create an effective anti-infective drugs (antiviral and antibacterial) means of plant origin revealed activity of flavonoid compounds exhibiting antiherpetic activity against herpes simplex virus type I (HSV-1) and are potential targets for development of anti-herpes drugs [3]. On the basis of this class of compounds have conducted research and development of drugs antiviral action, which was previously created "Alpizarin", and later - drug antiviral agent flavonoid nature, hereinafter Fitosanitary representing dry purified standardized extract (containing not less than 55% of the amount of flavonoids), obtained from the aerial parts (grass) two plants of the legume family (Fabaceae): the wild lespedeza kopeechnikovaya (Lespedeza hedysaroides Rail. Kitag) and herbs cultivated plant desmodium canadian (Desmodium canadense D..).

Fitosanitario of both plant species was obtained according to the following scheme: the above-ground part was extracted with water and Speer the new mixture, was purified from ballast substances are lipophilic in nature. The amount of flavonoids purified from the aqueous extract was extracted n-butyl alcohol, saturated with water. Removing the partially evaporated, purified and dried at 170-75°C in a vacuum drying Cabinet [4].

The biological activity of hitosubashi isolated from the herb of lespedeza kopeechnikovaya (Halpin"), or from the grass desmodium canadian (Halpin D"), due to the presence of amounts of flavonoids, are similar in composition, whose main ingredients are isovitexin, vitexin, isoorientin. Preliminary studies have shown that the pharmacological activity of the individual components does not exceed one compared to the amount of natural flavonoids. Fitosanitary is an amorphous powder from light brown to dark brown color with a specific smell.

In experimental and clinical studies of different years associated with phytosubstances derived from both plants, the objective comparative assessment of the results used names (which happened them permission for use in medical practice): Fitosanitary of lespedeza kopeechnikovaya - Halpin", and similar Hitosubashi from desmodium canadian added the letter D "Helpin D [5, 6].

Studies have shown the presence of the same Farmak is a logical activity, the absence of toxic properties and high equivalent clinical efficacy with the same infectious-inflammatory nosological forms, on the basis of which Halpin, Halpin D approved for use in medical practice as antiviral agents [5-7].

The invention expands the Arsenal of drugs used for the treatment of diseases occurring on the background of secondary immunodeficiency States.

The problem is solved by the use of Helaina or Helaina D as an immune-modulating means with secondary immunodeficiency.

Carried out experimental study of Helaina or Helaina D against herpes simplex virus (in vitro and in vivo) and pathogenic bacteria (in vitro).

A comparative study in vitro experiments showed the presence of both drugs the same verosimilitudes effect, manifested in the attitude of herpes simplex virus at a concentration of 10 μg/ml in experiments In vivo on the model of herpes encephalitis white mice, Halpin, Halpin D when introduced subcutaneously or intragastrically had equally positive chemotherapeutic effect, leading to 30-80% or 20-70%, respectively, of the survival rate of mice, with 100% mortality in the control. Study of antimicrobial activity showed that Hel is in Helpin D inhibited (at a concentration of 200-500

μg/ml) growth and development of microorganisms of the genus Staphylococcus, Proteus, Pseudomonas.

The study of acute (single dose) and chronic (when administered within 3 months) toxicity of Hitosubashi isolated from lespedeza kopeechnikovaya (Heleen) or desmodium canadian (Halpin D), showed the same security and the absence of any toxic effects on the major organs and systems of the organism of laboratory animals: blood hematological and biochemical parameters, the functional state of the liver and kidneys, Central nervous system and the cardiovascular and immune systems.

Experimental Toxicological studies of dosage forms revealed no contraindications for clinical trials of Helaina or Helaina D as the ingestion of tablets (0.1 g)and external use (5% and 1% ointment).

Clinical application of Helaina or Helaina D as obscherezorbtivnymi (pill) and local (ointment) antiviral agents in infectious-inflammatory diseases of viral, postirochnoy or suspected viral etiology in 936 patients adults and children (over 7 years) and 149 children aged from 1 year to 14 years showed good tolerance (in any case, no side effects) and high (80% to 100%) of therapeutic effect.

The study of specific types of toxicity is yamila Helaina or Helaina D allergenic, irritant, mutagenic, teratogenic and embryotoxic properties. The prototype - Alpizarina - established the presence of embryotoxic action, what was the reason to consider pregnancy a contraindication when using it in medical practice.

Further investigation revealed Helaina and Helaina additional pharmacological properties, namely anti-inflammatory, hepatoprotective, diuretic and hypoazotemic known to date.

In experiments on the study of specific types of toxicity unexpectedly revealed the presence of immunomodulatory properties (example 1).

Example 1. The study of immunomodulatory properties of Hitosubashi isolated from lespedeza kopeechnikovaya (Heleen) or desmodium canadian (Halpin D) and Alpizarina.

Method. Assessment of the impact of Hitosubashi and Alpizarina humoral immunity were performed on Wistar rats (males, 180-200 g). The drugs were injected into the stomach at doses of 1, 10 and 100 mg/kg for 4 weeks, after which animals were immunized optimal dose of sheep erythrocytes (EB) (5×108) and the immune response to heterogeneous erythrocytes was assessed at 5 days after antigenic load. The results of the experiment were determined by the titer of antibodies to EB in Microtest of haemagglutination and quantity anticolor is based on cells (AFC) in the spleen. The number of KLA was determined by the method of local hemolysis in the modification Cunningham. The impact of Hitosubashi and Alpizarina cellular immunity was performed in a reaction of hypersensitivity of the delayed type (GST) in mice CBA/Lac (males, 20-22 g)were immunized by subcutaneous injection in the interscapular area with sheep red blood cells at a dose of 2×108cells per mouse).

Fitosanitary and Alpizarin was administered to mice once intraperitoneally at doses of 1, 10 and 100 mg/kg per day before immunization EB ("D-1"), while immunization (D-0) and 24 hours after injection of the antigen ("D+1"). Control mice received intraperitoneally in "D+1" corresponding to the number - of 0.85% NaCl solution. On the 5th day after immunization, all animals received subplantar in the left hind paw allowing injection of EB dose of 5×108cells per mouse in a volume of 50 μl (advanced tab). In the tip of the contralateral paw (foot control) was administered 50 μl of 0.85% NaCl solution. The results of the reaction were recorded after 24 hours by weighing the "control" and "experimental" paws: the difference in their mass characterized the magnitude of the edema and the intensity of the reaction GST. The index of the reaction was calculated by the formula: U=[(m0-mk)/mk]×100%, where m0- weight experienced tarsi; mk- weight control tabs. In addition, performed the determination of phagocytic activity of blood neutrophils (PSOne-phagocytic index JFI) in Wistar rats treated Fitosanitario and Alpizarin at doses of 1, 10 and 100 mg/kg for 4 weeks.

Results. Experiments have shown (table 1)that long-term administration of Hitosubashi (Heleen or Helpin D) in the stomach of rats almost equally led to the activation of humoral immunity, with the most pronounced effect was observed at the dose of 1 mg/kg

The introduction of Hitosubashi dose of 1 mg/kg increased the number of AFC in the spleen about 4 times. Increasing doses of Hitosubashi 10 and 100 times does not lead to an increase in the number of KLA. While the hemagglutinin titer in the serum of the most high was observed after introduction of Hitosubashi dose of 1 mg/kg Introduction Alpizarina in the same conditions of experience in doses of 1, 10 and 100 mg/kg resulted in dose-dependent immunostimuliruyushhim effect. Investigation of the influence of Hitosubashi and Alpizarina cellular level showed no effect on the effectors of cellular immunity in response GST, but showed an increase in 2-3 times phagocytic activity of leukocytes, indicating the strengthening of the overall resistance of the organism of experimental animals under the influence of Hitosubashi and Alpizarina. Fitosanitary and Alpizarin, approximately to the same extent, increased nonspecific immunity, increasing opsona-phagocytic index (drawing).

Studies have shown, topicsubscriber, selected from lespedeza kopeechnikovaya (Heleen) or desmodium canadian (Halpin D), and Alpizarin in experiments on animals in all tested doses stimulated the formation of antibodies to a thymus-dependent antigen, increases the activity of the effectors of humoral immunity. However, the maximum immunostimulating effect Alpizarina manifested only in the high dose of 100 mg/kg, Hitosubashi immunostimulating effect was manifested in the lower (close to therapeutic) doses (1-10 mg/kg). Experiments have shown that Fitosanitary and Alpizarin about the same degree increased nonspecific immunity, increasing opsona-phagocytic index (drawing).

Thus, this experimental study Hitosubashi isolated from both types of plant material, allowed us to identify new pharmacological property immunomodulatory, which can contribute not only to improving the quality of anti-infective treatment, but also to broaden the range of applications in medical practice, including infectious and inflammatory diseases on the background of secondary immunodeficiency States.

In the clinical setting for the treatment of viral complications in patients with severe diseases of other etiologies (oncological diseases of the blood and lymphatic system, purulent-Vespa is sustained fashion CNS), causing secondary immunodeficiency, showed immunomodulating properties declared Hitosubashi.

These studies were performed in 2 specialized medical institutions: the Institute of children's infections (Hospital CNS) city of St. Petersburg; TO Institute WANTS RAMS (Department of Hematology).

141 patients aged 2 to 14 years with acute and recurrent herpes extragenital and genital localization, shingles and herpetiformis eczema sarcoma, cancer, psoriasis and other applied Fitosanitario inside tablets (0.1 g) and/or local (1% ointment). Feature clinical research Hitosubashi was that children being treated at the Clinic of CNS research Institute DI (Saint-Petersburg) and the Department of pediatric Hematology Institute TO WANTS RAMS, the use of Hitosubashi for viral infections (herpes infection, respiratory infection, contact with chickenpox) proceeded against the background of the treatment of severe major diseases of other etiologies (purulent-inflammatory diseases of the Central nervous system, cancer of the blood and lymph). Children with cancer and neuropathologies Fitosanitario used on the background of the special treatment of the underlying disease. When abortive form of herpes is only used by external application of a 1% ointment Helaina D, which was applied to the lesions on kozaily mucous membranes 4-6 times a day. In generalized forms and phenomena of intoxication (fever, aches, chills, and other) at the same time gave the pills to 0.1 g orally in the age dosages. Patients herpetiformis eczema Kaposi additionally received special treatment.

Clinical studies have shown that Hitosubashi with various forms of viral lesions in children, even weakened by other severe illness (meningitis, hematological malignancies, and others), is more effective than traditional therapy. At follow-up within 6 months these children relapses were not observed. In children with various forms of malignant neoplasms of the hematopoietic and lymphatic tissues (secondary immunodeficiency) application of Hitosubashi for the treatment of viral infections (Herpes simplex, Herpes zoster, infection, contact chickenpox) showed its high efficiency in the complete absence of side effects. Of special interest is the evidence of the effectiveness of Hitosubashi for acute respiratory infections in the etiology of which, as we know, there may be a variety of viruses, including Reno and adenoviruses (samples №№2, 3).

Example 2. Clinical studies of Helaina D in viral complications, conducted at the Clinic of CNS research Institute of children's infections (Saint-Petersburg).

The scope of the study. Research the s was carried out to identify therapeutic efficacy of the drug in 16 children with acute and recurrent herpetic infection of the skin of the face and hands and mucous membranes of the oral cavity and nasopharynx, receiving inpatient treatment for purulent meningitis (10 children) and other infectious and inflammatory diseases of the Central nervous system: neuritis of the cranial nerves, tick-borne encephalitis and other (6 children). Against the background of these diseases in 9 children diagnostirovalis herpes lips, have 5 children - herpes person, 1 child - herpetic stomatitis, 1 - herpes right palm. In 12 patients the lesions were expressed in a moderate way, and without the presence of swelling, neuralgia, increased or painful lymph nodes. In 4 children in the appearance of herpetic lesions was accompanied by fever and General malaise for 2 days. At the same time under observation (outpatient) were 10 adults (parents, staff offices)in contact with sick children and suffering from acute or recurrent herpetic infection. All 10 adult patients infection manifested herpetic skin lesions of the face, lips, stomatitis, 7 patients were observed by a combination of symptoms on the background of significant General malaise: fever (up to 37.5°) and autonomic disorders (lacrimation, sweating, vascular injection of the sclera) within 3-5 days.

Method. Helpin D was administered to children in the form of tablets 0.1 g (inside) and 1% ointment (lesions). Dose corresponded to Jalepino previously permitted as protivo the funds originate. The course of treatment in children ranged from 4 to 15 days in adults is 10-20 days. Of the 16 children, 11 had received both the pill and topical treatment with 5 children - only the ointment. All 10 adult patients received simultaneously pills and ointment 5%.

Results. Clinical effect was reached on average 3-4 days of treatment: decreased swelling disappeared vegetative disturbances, fever, there was a subjective improvement of the patient. After 4-5 days in patients observed drying herpes elements, 7-10 - days falling crusts. Dynamics laboratory values of clinical blood analysis showed a decrease in leukocyte count and erythrocyte sedimentation rate in 2 times, and increased in 4 times the number of lymphocytes, indicating immunokorrigiruyuschy action of Helaine D. in Addition, significant improvement in clinical urine analysis (table 2). The results of treatment with Helaina D testify to the complete safety of this medicine, do not cause pathological changes in the organism of the patient, allergic or other reactions.

Effectiveness according to Clinic CNS research Institute of children's infections in all patients, children and adults was 100% (table 3). Helpin D is effective and do not produce side effects in the treatment of herpetic skin lesions of the face and hands, as well as mucous about the shell of the oral cavity and nasopharynx in children and adults on the background of secondary immunodeficiency States.

Along with high antiviral activity, remaining in the background of secondary immunodeficiency, declared Fitosanitary has immunocorrective action on the organism of patients with secondary immunodeficiency state.

Example 3. Use as antiviral agents of Helaina D on the background of cancer (according to data from the Department of pediatric Hematology TO Institute WANTS RAMS).

The scope of the study. Helpin D in the form of tablets of 0.1 g and 1% ointment used patients with hematological malignancies, acute viral infections. Treatment Helaina D conducted in 54 children (aged 4 to 14 years) with primary diagnosis in 32 children - chlamydia, 21 - lymphosarcoma, 1 - teratoma of the mediastinum, 28 children had generalized disease stage III-IV. The 12 children was diagnosed with a relapse of the underlying disease. The children were at various stages of special software treatment (chemotherapy, radiotherapy). Besides children treatment Helaina D received 7 adults (staff Offices) with a viral infection.

Indications for use as antiviral agents of Helaina D were: accession herpes infection, acute respiratory viral infection and contact with chickenpox. Herpes simplex was observed in 16 children with different localization of herpetic lesions: is blasti - lips 15 children, in the area of the nose - 1. All children reported fever (up to 38.5°C) for 1-2 days. Helpin D was administered at 1-3 days (from the appearance of herpetic lesions) in the form of tablets of 0.1 g 3 times a day and 1% ointment at the same time within 3-5 days.

Results. In 11 children with Herpes simplex noted (table 4) the formation of the crust over 2 days and the cleansing of the skin for 3-4 days. Have 3 children, despite the full effect in the area of primary focus, for 5-6 day use of the drug noted the emergence of new areas herpetic lesions, and the treatment continued. Have 2 children effect when the drug was absent.

Herpes zoster was observed in 7 children with different localization of lesions in the chest and back (3), throughout the right limb (1), scalp (1), ear (1), in the anterior abdominal wall (1). Vesania was accompanied by pain, itching, fever (up to 38-39°). Helpin D was administered in the form of tablets (0.1 g 3-4 times a day) and 1% ointment (2-4 days from the beginning of infection within 5-10 days). In 3 children came to the relief of fever, pain and itching, as well as the termination of the current evidence on the 2nd day of taking the drug, have 4 children - relief distribution process and complete recovery to 10 days.

For the prevention of varicella, Halpin D appointed 2 children 0.1 g 3 times a day for 5 days due to the right near St the only contact with chickenpox. Development of varicella has not come.

In acute respiratory viral infections tablet Helaina D appointed 38 children with various forms of hematological malignancies at the time of accession of the symptoms of SARS in a daily dose of 0.1 g 3-4 times a day for 5-7 days. 31 children showed improvement in 3-4 days of using the medication and complete relief for 4-5 hours, in 3 children is an infectious process was controlled for 7-9 days, 5 children the use of Helaina D had no effect. Side effects of Helaina D not noted in any case.

Based on the results of clinical studies of Helaina D in the Department of pediatric Hematology TO Institute WANTS RAMS in children with various forms of malignant neoplasms of the hematopoietic and lymphatic tissues, which had a concomitant viral infection (Herpes simplex et zoster, infection, contact chickenpox), a high efficiency of Helaina D in the complete absence of side effects. It is known that secondary immunodeficiency associated with tumor development and increasing use of intensive chemo therapy, contributes to rapid development in this category of patients with viral infections, which usually take a severe and protracted course and make it difficult to implement a special basic therapy. In this regard, Halpin D, with p tivolitryne and immunocorrective properties provided substantial assistance in the treatment of children with severe tumor pathology, leading to the development of secondary immunodeficiency.

The positive effect is the establishment of an immunomodulatory properties declared Hitosubashi (Halpin D or Halpin), with secondary immunodeficiency:

in a clinical setting manifestation of immunocorrective properties on the organism of patients with secondary immunodeficiency state and maintaining a high therapeutic antiviral effect in infectious and inflammatory diseases, occurring against the background of secondary immunodeficiency;

in experimental conditions, the establishment of the immunomodulatory properties of the effectors of humoral immunity, increasing the overall resistance of the organism of laboratory animals and the identification of safety in acute and chronic experiments.

Sources of information

1. Vechkanov S.A., Ludhiyana, Viglain. "Antiviral agent alpizarin". USSR author's certificate No. 1336301. Patents: England No. 2108383; U.S. No. 4436732, CL AC 37/02,1989; France, No. 81198820; Germany No. 31411970.

2. EN 23089612, 27.10.2007.

3. Vechkanov S.A., Shipulina L.D., Bankowski A.I., Glyzin VI, sheljuto V.L. Flavonoid compounds exhibiting anti-herpes activity. Copyright certificate №491387 priority from 18.07.1974, GOS. Register of Fig. The SSR 22.07.1975,

4. The Glyzin VI, anolis VP, Vechkanov S.A., Shipulina L.D., Perelson ON the Way to obtain the antiviral drug "Helpin". Copyright certificate №648032 priority from 20.09.1977, GOS. Register of Fig. The USSR 20.10.1978,

5. The state register of medicines. - Volume 1. - M - 2006. - P.88, 514 (Heleen).

6. The state register of medicines. - Volume 1. - M - 2006. - P.88, 514 (Halpin D).

7. Mashkovsky PPM Medicines. - Part II. - M - 1993. - S.

Table 1
The impact of Hitosubashi isolated from lespedeza kopeechnikovaya (Heleen) or desmodium canadian (Halpin D), indicators of humoral immunity in rats in comparison with Alpizarinom at 4-week introduction.
Version of the experiment, Dose, mg/kgThe studied parameters
The number of AFC in the spleenReverse hemagglutinin titer in serum
Control19680±56002,3±0,4
Helpin 172000±68300**10,3±1,5**
Helpin 1051120±4400*5,7±0,2*
Helpin 10045250±4320*5,3±0,2*
Control16200±32002,5±0,4
Halpin D. 164000±5300**11,2±1,6**
Helpin D 1042320±3100*6,4±0,3*
Helpin D 10034140±3110*5,0±0,2*
Control39600±29003,7±0,3
Alpizarin 1113100±3290**8,0±1,3**
Alpizarin 10138600±3880**7,6±0,6**
Alpizarin 100192600±3270**16,0±0,1**

Table 3
The effectiveness of Hitosubashi isolated from desm is diuma canadian, when herpes infection in 16 children (on the background of severe purulent-inflammatory diseases of the Central nervous system) and 10 adults (through contact with infected children) *
Nosological formnPositive effects, %/n1**The lack of effect
Herpes of the lips12100/120
Herpes skin6100/60
Herpetic stomatitis1100/10
The combination of syndromes7100/70
Total:26260
*) According to Clinic CNS research Institute of children's infections
**) n1the number of patients with a positive effect

That the face 4
The effectiveness of Hitosubashi isolated from desmodium canadian, in viral infections in 54 children with oncological diseases of the blood and lymphatic system and 9 adults (contact with infected children)
DiagnosisnEfficiencyNo effect
100%>50%
Herpes simplex161132
Herpes zoster7340
ARI383125
Chickenpox (contact)2200
Total:63
*) According to the Department of pediatric Hematology TO Institute WANTS RAMS

The use of Helaina D or Helaina as immune-modulating means with secondary immunodeficiency.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely pulmonology, and can be used for treating community-acquired pneumonia in the patients with mid-severe and severe clinical course involving immunogram abnormalities. That is ensured by antibacterial therapy. In addition, for 3-4 day of treatment, the treatment regimen is supplemented with Polyoxidonium in a dose 6 mg daily intramuscularly within 5 days.

EFFECT: early positive dynamics of the main clinical symptoms of disease and normalisation of immunological indicators which allow reducing treatment time and preventing complications.

1 tbl, 1 ex, 1 dwg

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary medicine, particularly to anthelmintic preparations for treating small cattle and can be used for treatment and prevention of helminthic invasions accompanied by reduced immunobiological properties. The anthelmintic preparation for treating small cattle contains albendazole, 40% Echinacea tincture, 4% methylcellulose - 100 and sorbic acid and distilled water in the ratio as follows, wt %: albendazole 2.5-5.0; 40% Echinacea tincture 9-12; 4% methylcellulose-100 20-25; sorbic acid 0.5-1.0; distilled water - the rest.

EFFECT: higher effectiveness and lower toxicity of the preparation.

2 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a new derivative of sulfonamide substituted imidazoquinolines, and specifically to N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo-[4,5-c]-qunolin-1-yl]-1,1-dimethylethyl}-methanesulfonamide and its pharmaceutically acceptable salts, as well as to a pharmaceutical composition based on this compound.

EFFECT: invention also relates to a method of inducing biosynthesis of cytokines in an animal organism and methods of treating viral and oncological diseases in animals using said compound and pharmaceutical composition based on said compound.

5 cl, 1 tbl, 39 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: invention relates to biotechnology and design of agents with immunomodulating properties. A new fungal strain Penicillium verrucosum VKPM F-984 and a new immunomodulating agent based on the strain are proposed. The strain is extracted from microflora of ginseng roots and is kept in a medium which contains mineral salts, glucose and asparagine. Fungus mycelium is extracted with a water-alcohol solution (70% ethanol solution). The advantage of this agent is its natural occurrence and effecient stimulation of adaptive capabilities of the body.

EFFECT: obtaining an extract which has stimulating action on cell and humoral immunity, improves immune status of the body.

3 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: in formulas (I) and (Ia) . A is 1-cyclopentene-1,2-diyl; Z1 and Z2 are O; E is phenyl substituted with 1-4 substituting groups selected from halogen, Y is phenyl substituted with 1-2 substituting groups selected from halogen, C1-C6alcoxy, halogen C1-C6alcoxy; the meaning of other radicals are indicated in the formula of the invention. The invention refers also to the pharmaceutical composition including the compound of the invention, to the application of the said compound at preparation of the medicinal agent and to the application for DHODH inhibition.

EFFECT: compound of the present invention can find application as medicinal agent inhibiting dehydroorotate dehydrogenase.

9 cl, 18 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to occupational diseases, and can be used for correction of immune alterations in persons being in contact with toxic substances. The method is carried out as follows. Introduction of immunostimulant Cyclopheron is preceded with individual adverse effect test by incubation in vitro of Cyclopheron and mononuclear cells separated from peripheral blood. Cyclopheron is introduced provided CD19+ B-lymphocyte count is exceeded by 20% and more, and activated HLA-DR+ lymphocyte count by 15% and more.

EFFECT: method allows improving effectiveness of correction of immune alterations owing to prediction of body's immune response to Cyclopheron therapy.

1 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel diazaindoledicarbonylpiperazinyl compounds of formula I, including its pharmaceutically acceptable salts, which possess antiviral activity and can be used for HIV-infection treatment. In compounds of formula I Q represents , T represents -C(O)- or -CH(CN)-; R1 represents hydrogen; R3 represents hydrogen; R5 is independently selected from group including halogen, cyano, XR9 and B; R2 and R4 are absent; R6 represents hydrogen; -- represents carbon-carbon bond; -Y- is selected from group including , each of R10, R11, R12, R13, R14, R15, R16 and R17 represents H; R18 is selected from group including C(O)-phenyl, isoquinolyl, quinazolyl; D is selected from group including cyano, 5-member heteroaryl containing 3 heteroatoms selected from nitrogen and oxygen; A is selected from group including phenyl, pyridinyl; B is selected from group including -C(O)CH3; piperazinyl; 5-, 6-member heteroaryl containing 1-3 N atoms and possibly O atom; where said heteroaryl optionally is substituted with from one to three similar or different substituents selected from F; F is selected from group including (C1-6)alkyl, phenyl, pyridinyl, COOR26, -COR21, and -CONR24R25; where phenyl is optionally substituted with (C1-6)alkoxy, CF3, or halogen atom; R9, R24, R25 and R26 each is independently selected from group including hydrogen and (C1-6)alkyl; X represents O; R27 represents piperazinyl, N-methylpiperazinyl, or 3-pirazolyl. Invention also relates to pharmaceutical composition.

EFFECT: obtaining compounds and pharmaceutically acceptable salts, which possess antiviral activity and can be used for treatment of HIV infection.

19 cl, 50 dwg, 4 tbl, 43 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely, to surgical stomatology and can be used at treatment of septic wounds of maxillofacial area. For this purpose the 4.16% cycloferon immunomodulator solution, prepared by its dilution with the 0.9% sodium chloride solution is injected into an exudative phase of a septic wound process against complex medicamental treatment in a wound on turundas. In case of the expressed exudation, the cycloferon solution is diluted with the 10% sodium chloride hypertonic solution. Dressings are performed daily. In a proliferative phase of a wound process cycloferon is injected into a wound a kind of 5% liniment, thus dressings are performed in a day. The way allows raising efficiency of complex treatment of patients with the given pathology without system influence on immune system at the expense of local cycloferon immunocorrection taking into account wound process phases.

EFFECT: increase of efficiency of complex treatment of patients with the given pathology without system influence on immune system at the expense of local cycloferon immunocorrection taking into account wound process phases.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely odontology and can be used for treatment of pyoinflammatory diseases of soft tissues of maxillofacial area. The way is carried out as follows. Roncoleukin is administered in the exudative-inflammatory phase of a purulent wound process in the form of a solution with 500000 ME dose of active substance, into a wound preliminary irrigated by means of 10.0 ml of sterile 0.9% sodium chloride, on the turundas, dilluted either with 0.9%, or 10% sodium chloride solution. Thus a bandage from 20% dimexid solution is imposed on periphery of a purulent wound, spending daily dressings. In a proliferative phase - an irrigation of a wound using the Roncoleukin solution is combined with 500000 ME dose of active substance, diluted with 0.9% solution of sodium chloride and salve dressings with preparations on a water-soluble basis; dressings are spent in a day. The way allows normalising indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

EFFECT: possibility to normalise indicators of local immunity of a purulent wound and an oral cavity, to strengthen functional activity of phagocytes of a wound, to accelerate purification of wounds from necrotic masses, to optimise terms of occurrence of granulations.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, and can be used for treatment of calicivirus intestinal infection at children. For this purpose simultaneously with symptomatic therapy children's anaferon is prescribed perorally. In the first days of disease anaferon is prescribed in a dose of 0.3 g each 30 minutes within 2 hours. Then 3 more tablets of 0.3 g at regular intervals. The next 4 days it is prescribed in a dose of 0.3 g 3 times a day.

EFFECT: reduction of terms of treatment at the expense of stimulation of development of endogenous interferons and activation of process of development of specific antibodies, restoration in short terms of a gastroenteric tract microbiocenosis.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to development of an antiaggregatory and stress-limiting agent as a reactant containing ecdysteroids-containing substance in the form of mixed 20-hydrohyecdysone in amount 75% and more, and 25S-inokosteron in amount 10% and more. The reactant is recovered from herb of Serratula sort of Asteraceae family, preferentially leaves collected during vegetation, mass budding or beginning of blossoming.

EFFECT: extended range of antiaggregatory and stress-limiting agents without manifesting the by-actions on a human body.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to development of an antiaggregatory and stress-limiting agent as a reactant containing ecdysteroids-containing substance in the form of mixed 20-hydrohyecdysone in amount 75% and more, and 25S-inokosteron in amount 10% and more. The reactant is recovered from herb of Serratula sort of Asteraceae family, preferentially leaves collected during vegetation, mass budding or beginning of blossoming.

EFFECT: extended range of antiaggregatory and stress-limiting agents without manifesting the by-actions on a human body.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to development of an antiaggregatory and stress-limiting agent as a reactant containing ecdysteroids-containing substance in the form of mixed 20-hydrohyecdysone in amount 75% and more, and 25S-inokosteron in amount 10% and more. The reactant is recovered from herb of Serratula sort of Asteraceae family, preferentially leaves collected during vegetation, mass budding or beginning of blossoming.

EFFECT: extended range of antiaggregatory and stress-limiting agents without manifesting the by-actions on a human body.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to production of medicinal, veterinary, cosmetic preparations, and also to food industry and agriculture. Ground pine bark is extracted with boiling 10-15% ethanol within 0.5-1.0 hours at water duty 1:10-15. The water-alcohol solution is separated from bark, concentrated to 1/4 of original volume, saturated with sodium chloride with filtering separation of made deposit. Filtrate is three-fold extracted with ethyl acetate, and ethyl acetate solution is vacuum concentrated to 1/5 of original volume. The concentrated ethyl acetate solution is 5-7-fold dissolved with chloroform with recovering proanthocyanidines.

EFFECT: higher yield of proanthocyanidines.

3 ex

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary medicine and can be used in large cattle-breeding complexes, farms and private economies. Substance of the invention implies that intrauterine suppositories for vulvovaginitis treatment and prevention in cows contains Vivaton, "АСД-2ф", chemically pure lanolin as an emulsifier, and cocoa butter as an excipient in the ratio per one suppository as follows, g: Vivaton 1.0; chemically pure lanolin 1.0; "АСД-2ф" 0.5; Cocoa butter 8.0. The method of application of intrauterine agent for vulvovaginitis treatment and prevention in cows according to cl. 1 involves daily intrauterine introduction with therapeutic dosage of 2 suppositories twice a day during 3-5 days, and preventing dosage 1 suppository once a day during 2-3 days.

EFFECT: vulvovaginitis treatment and prevention in cows.

4 cl, 4 tbl, 2 ex

FIELD: veterinary science.

SUBSTANCE: invention refers to veterinary medicine, particularly to anthelmintic preparations for treating small cattle and can be used for treatment and prevention of helminthic invasions accompanied by reduced immunobiological properties. The anthelmintic preparation for treating small cattle contains albendazole, 40% Echinacea tincture, 4% methylcellulose - 100 and sorbic acid and distilled water in the ratio as follows, wt %: albendazole 2.5-5.0; 40% Echinacea tincture 9-12; 4% methylcellulose-100 20-25; sorbic acid 0.5-1.0; distilled water - the rest.

EFFECT: higher effectiveness and lower toxicity of the preparation.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention describes application of compound which has formula or its salt for prevention or reduction of biofilm formation on abiotic surface or for prevention or reduction of viable microbes growth on abiotic surface, where R1 represents straight or branched alkyl group containing from 8 to 16 carbon atoms in the 2-nd or 3-d position of morpholene ring and R2 represents straight or branched alkyl group containing from 2 to 10 carbon atoms substituted with hydroxy group, except in alfa-position, sum of carbon atoms in groups R1 and R2 constituting at least 10 and preferably 20. Abiotic surface is a medical device, device for fluid medium storage, device of fluid storage delivery or surgical instrument.

EFFECT: invention ensures non-viability of any bacterial biofilm.

20 cl, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention describes application of compound which has formula or its salt for prevention or reduction of biofilm formation on abiotic surface or for prevention or reduction of viable microbes growth on abiotic surface, where R1 represents straight or branched alkyl group containing from 8 to 16 carbon atoms in the 2-nd or 3-d position of morpholene ring and R2 represents straight or branched alkyl group containing from 2 to 10 carbon atoms substituted with hydroxy group, except in alfa-position, sum of carbon atoms in groups R1 and R2 constituting at least 10 and preferably 20. Abiotic surface is a medical device, device for fluid medium storage, device of fluid storage delivery or surgical instrument.

EFFECT: invention ensures non-viability of any bacterial biofilm.

20 cl, 3 tbl, 1 ex

FIELD: cosmetology.

SUBSTANCE: invention is related to perfume-cosmetic field, namely to perfume composition, which includes the following components in cosmetically acceptable medium: a) at least 2 wt % of fragrant substance of the overall mass of composition; b) at least one filter A of hydroxyaminobenzophenone type; c) at least one filter B of cinnamate type; d) at least one compound C selected from the following: i) compound of piperidinol type; ii) at least one compound of benzotriazole type; iii) UV-filter of dibenzoylmethane type.

EFFECT: invention makes it possible to produce perfume products, which have organoleptic properties, such as smell and colour, that remain stable with course of time and under action of light or temperature difference.

15 cl, 13 ex

FIELD: cosmetology.

SUBSTANCE: invention is related to perfume-cosmetic field, namely to perfume composition, which includes the following components in cosmetically acceptable medium: a) at least 2 wt % of fragrant substance of the overall mass of composition; b) at least one filter A of hydroxyaminobenzophenone type; c) at least one filter B of cinnamate type; d) at least one compound C selected from the following: i) compound of piperidinol type; ii) at least one compound of benzotriazole type; iii) UV-filter of dibenzoylmethane type.

EFFECT: invention makes it possible to produce perfume products, which have organoleptic properties, such as smell and colour, that remain stable with course of time and under action of light or temperature difference.

15 cl, 13 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!